Home-Based tDCS Treatment Of Major Depressive Disorder
NCT: NCT06976697 · RECRUITING
Brief Summary
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
Frequently Asked Questions
What is Home-Based tDCS Treatment Of Major Depressive Disorder?
Home-Based tDCS Treatment Of Major Depressive Disorder is a clinical trial registered under NCT06976697. Current status: RECRUITING.
What is the status of NCT06976697?
The current status of NCT06976697 (Home-Based tDCS Treatment Of Major Depressive Disorder) is: RECRUITING.
When did Home-Based tDCS Treatment Of Major Depressive Disorder start?
Home-Based tDCS Treatment Of Major Depressive Disorder started on 2025-06-27.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.